| Bid | 0.2 |
| Market Cap | 12.36M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.92 |
| PE Ratio (ttm) | -0.07 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.21 |
| Volume | 387,340 |
| Avg. Volume (20D) | 6,791,393 |
| Open | 0.20 |
| Previous Close | 0.20 |
| Day's Range | 0.20 - 0.21 |
| 52-Week Range | 0.13 - 2.30 |
| Beta | undefined |
About APTO
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Ph...
Analyst Forecast
According to 3 analyst ratings, the average rating for APTO stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 2335.46% from the latest price.
9 months ago · seekingalpha.com
Aptose Biosciences Inc. (APTO) Q4 2023 Earnings Call TranscriptAptose Biosciences Inc. (APTO) Q4 2023 Earnings Call Transcript
2 years ago · seekingalpha.com
Aptose Biosciences Continues To Drift Without Thesis-Changing DataAptose has made some progress in the clinic this year, including additional complete responses for lead program HM43239 and a new formulation of luxeptinib. Expansion studies of '239 in 2023 could pav...
